Meeting
2020 ASCO Virtual Scientific Program
Selinexor, daratumumab, and dexamethasone in patients with relapsed/refractory multiple myeloma (MM).
Authors
Cristina Gasparetto
Duke University Cancer Center, Durham, NC
Cristina Gasparetto , Suzanne Lentzsch , Gary J. Schiller , Natalie Scott Callander , Sascha Tuchman , Nizar J. Bahlis , Darrell White , Christine Chen , Muhamed Baljevic , Heather J Sutherland , Rami Kotb , Michael Sebag , Richard LeBlanc , Christopher P Venner , William Bensinger , Adriana C. Rossi , Heidi Sheehan , Melina Arazy , Kazuharu Kai , Brea Lipe
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies
Sub Track
Multiple Myeloma
Clinical Trial Registration Number
NCT02343042
Citation
J Clin Oncol 38: 2020 (suppl; abstr 8510)
DOI
10.1200/JCO.2020.38.15_suppl.8510
Abstract #
8510
Poster Bd #
410
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Once weekly selinexor, carfilzomib, and dexamethasone (SKd) in patients with relapsed/refractory multiple myeloma (MM).
First Author: Cristina Gasparetto
Poster
2021 ASCO Annual Meeting
Once weekly selinexor, carfilzomib, and dexamethasone (XKd) in carfilzomib nonrefractory multiple myeloma (MM) patients.
First Author: Cristina Gasparetto
Poster
2023 ASCO Annual Meeting
Ixazomib and daratumumab without dexamethasone (I-Dara) in elderly frail patients with RRMM: Results of the multicenter phase 2 study (IFM 2018-02) of the Intergroupe Francophone du Myélome (IFM).
First Author: Cyrille Touzeau
Poster
2016 ASCO Annual Meeting
Phase I trial of the combination of selinexor (SEL), liposomal doxorubicin (DOX) and dexamethasone (Dex) for relapsed and refractory multiple myeloma (RRMM).
First Author: Rachid C. Baz